Differential Effects of GLP-1 Receptor Agonist on Foam Cell Formation in Monocytes Between Non-obese and Obese Subjects
Overview
Authors
Affiliations
Objective: Monocytes/macrophages (Mϕ) transform into foam cells in the presence of oxidized-LDL (ox-LDL), releasing inflammatory mediators. The antiatherogenic role of a dipeptidyl peptidase-4 inhibitor is mediated, in part, through improving the unbalance of inflammatory (M1)/anti-inflammatory (M2) phenotypes in monocytes. In this study, we examined differential regulation of glucagon-like peptide-1 receptor (GLP-1R) signaling for antiatherogenesis in monocytes/Mϕ from normal-weight control subjects and obese patients.
Methods: We evaluated the effects of exendin-4 (Ex-4), a GLP-1R agonist, on ox-LDL-stimulated foam cell formation, M1/M2 cytokine production, and organelle change in primary monocytes from control subjects and obese patients and human monocytic THP-1-derived Mϕ as well.
Results: Here we report that Ex-4 suppressed foam cell formation and M1 cytokine expression and, interestingly, induced indicators of autophagy in ox-LDL-stimulated monocytes from control subjects. The suppressing effects on foam cell formation by Ex-4 were reversed by a cAMP inhibitor. In contrast to control subjects, Ex-4 did not induce indicators of autophagy, but did induce foam cell formation and M1 cytokine expression in monocytes from obese patients. GLP-1R expression level was comparable between control subjects and obese patients. The effects of Ex-4 on inducing indicators of autophagy and suppressing foam cell formation were observed in THP-1 Mϕ.
Conclusions: These data suggest that GLP-1R signaling induces autophagy, thereby suppressing foam cell formation in non-obese subjects. In obese patients, GLP-1R stimulation increased foam cell formation and IL-6, TNF-α, and IL-1β production. Such altered signaling in monocytes of obese patients may be involved in the development of atherosclerosis.
Kamarullah W, Pranata R, Wiramihardja S, Tiksnadi B Am J Cardiovasc Drugs. 2024; 25(2):203-229.
PMID: 39616304 DOI: 10.1007/s40256-024-00695-9.
Cebi M, Yilmaz Y Front Immunol. 2024; 15:1445634.
PMID: 39148730 PMC: 11324455. DOI: 10.3389/fimmu.2024.1445634.
Hachula M, Kosowski M, Ryl S, Basiak M, Okopien B Int J Mol Sci. 2024; 25(3).
PMID: 38339133 PMC: 10855444. DOI: 10.3390/ijms25031854.
Piccirillo F, Mastroberardino S, Nusca A, Frau L, Guarino L, Napoli N Int J Mol Sci. 2023; 24(12).
PMID: 37373310 PMC: 10299555. DOI: 10.3390/ijms241210164.
Patti A, Giglio R, Allotta A, Bruno A, Di Bella T, Pantea Stoian A Biomedicines. 2023; 11(5).
PMID: 37239033 PMC: 10216597. DOI: 10.3390/biomedicines11051362.